Real-World Effectiveness of Nirmatrelvir/Ritonavir on Covid-19-Associated Hospitalization Prevention: A Population-Based Cohort Study in the Province of Québec, Canada.

Jean-Luc KaboréBenoît LaffontMamadou DiopMelanie R TardifAlexis F TurgeonJeannot DumaresqMe-Linh LuongMichel CauchonHugo ChapdelaineDavid ClaveauMarc BrosseauElie HaddadMike Benigeri

Published in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023)

Nirmatrelvir/ritonavir reduces the risk of COVID-19-associated hospitalization among incompletely vaccinated high-risk outpatients and among some subgroups of completely vaccinated high-risk outpatients.

Keyphrases

coronavirus disease
sars cov
randomized controlled trial
antiretroviral therapy
south africa
systematic review
respiratory syndrome coronavirus